# INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

> **NCT03838042** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital Heidelberg** · enrollment: 91 (estimated)

## Conditions studied

- CNS Tumor
- Solid Tumor

## Interventions

- **DRUG:** Nivolumab and Entinostat

## Key facts

- **NCT ID:** NCT03838042
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-26
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03838042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03838042, "INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT03838042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*